---
title: "Medtronic diabetes business carve-out MiniMed prices IPO at $20, below the range"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278022951.md"
description: "MiniMed Group, a spin-off from Medtronic's diabetes business, has priced its IPO at $20 per share, raising $560 million, below the expected range of $25 to $28. The company, focusing on integrated diabetes management, has a market cap of $5.6 billion and serves over 640,000 insulin pump users. Approximately 83% of its revenue comes from continuous glucose monitors and related services. MiniMed plans to list on Nasdaq under the symbol MMED, with several major banks acting as joint bookrunners for the offering."
datetime: "2026-03-06T03:43:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278022951.md)
  - [en](https://longbridge.com/en/news/278022951.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278022951.md)
---

# Medtronic diabetes business carve-out MiniMed prices IPO at $20, below the range

MiniMed Group, a carve-out of Medtronic's diabetes management devices and technology business, raised $560 million by offering 28 million shares at $20, below the range of $25 to $28. At the pricing, the company commands a market cap of $5.6 billion.

Being carved out of Medtronic, MiniMed focuses on integrated diabetes management, including insulin delivery devices, continuous glucose monitors (CGMs), infusion sets, reservoirs, pen systems, and related software and services. The company’s user base exceeds 640,000 individuals on insulin pumps as of October 2025 and its CGM attachment rate reached 65% in the six months ended October 24, 2025 (versus 58% in the prior period). Approximately 83% of total revenue is generated by CGMs, other consumables, software, and services, which reflects the durability of its recurring sales model.

MiniMed Group plans to list on the Nasdaq under the symbol MMED. Goldman Sachs, BofA Securities, Citi, Morgan Stanley, Barclays, Deutsche Bank, Mizuho Securities, Wells Fargo Securities, Evercore ISI, and Piper Sandler acted as joint bookrunners on the deal.

### Related Stocks

- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Medtronic stock is defying a market selloff after earnings. Here's why.](https://longbridge.com/en/news/288593490.md)
- [Top Medtronic Executive Makes Notable Move With Fresh Stock Sale](https://longbridge.com/en/news/289274660.md)
- [BUZZ-Street View: Medtronic moves from 'show me' story to 'trust the setup' story](https://longbridge.com/en/news/288713684.md)
- [Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care | MDT Stock News](https://longbridge.com/en/news/289615773.md)
- [Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years | MDT Stock News](https://longbridge.com/en/news/288561177.md)